
Absci Inc. (NASDAQ:ABSI) on Thursday collaborated with Oracle Corporation’s (NASDAQ:ORCL) Oracle Cloud Infrastructure (OCI) and AMD Inc. (NASDAQ:AMD) to accelerate generative AI-driven drug discovery.
Absci’s generative AI Drug Creation Platform leverages OCI’s AI infrastructure and AMD’s latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.